Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §3

Draft monograph: danuglipron — disposition

The disposition of every submission and the amendments that resulted.

Document identifier
CEI-CP-031/3
Series
Public comment period
Version
1.0
Published
16 Sep 2025
Last reviewed
16 Sep 2025
Next review
16 Sep 2026
Identifier
10.71829/cei.cp.31
Certainty
Not rated
Cycle
2025 Q3
Window
14 Jul 2025 – 25 Aug 2025
Status
Closed
Submissions
3

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

ReferenceRespondentPoint raisedDisposition
DRAFT-DANUGLIPRON-/001Dr Yusuf Whitmarsh-ObiOpen-label extension data are presented alongside randomised data without distinctionAccepted
DRAFT-DANUGLIPRON-/002Dr Frideswide NordhagenDoses are expressed in units that differ between sectionsAccepted
DRAFT-DANUGLIPRON-/003Dr Rurik Haverkamp-DialloThe monograph should not describe how the compound is supplied outside a regulated routeNoted, no amendment
3 submissions in total.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

DispositionCountMeaning
Accepted2The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.
Accepted in part0Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.
Noted, no amendment1The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.
Not accepted0The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

§3.3Resulting amendments

  1. Open-label extension data are presented alongside randomised data without distinction — arising from DRAFT-DANUGLIPRON-/001. Extension data now appear in a separate table headed as uncontrolled follow-up, with a standing note on differential withdrawal.
  2. Doses are expressed in units that differ between sections — arising from DRAFT-DANUGLIPRON-/002. A single dose unit is now used throughout each monograph, with the source unit retained in parentheses wherever a conversion was applied, and every conversion is stated rather than performed silently.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.